461 related articles for article (PubMed ID: 33984678)
1. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort.
Fornarini G; Rebuzzi SE; Banna GL; Calabrò F; Scandurra G; De Giorgi U; Masini C; Baldessari C; Naglieri E; Caserta C; Manacorda S; Maruzzo M; Milella M; Buttigliero C; Tambaro R; Ermacora P; Morelli F; Nolè F; Astolfi C; Sternberg CN
ESMO Open; 2021 Jun; 6(3):100118. PubMed ID: 33984678
[TBL] [Abstract][Full Text] [Related]
2. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
3. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
[TBL] [Abstract][Full Text] [Related]
4. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
Banna GL; Cortellini A; Cortinovis DL; Tiseo M; Aerts JGJV; Barbieri F; Giusti R; Bria E; Grossi F; Pizzutilo P; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Marco R; Cantini L; Nigro O; D'Argento E; Buti S; Minuti G; Landi L; Guaitoli G; Lo Russo G; De Toma A; Donisi C; Friedlaender A; De Giglio A; Metro G; Porzio G; Ficorella C; Addeo A
ESMO Open; 2021 Apr; 6(2):100078. PubMed ID: 33735802
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab.
Banna GL; Signorelli D; Metro G; Galetta D; De Toma A; Cantale O; Banini M; Friedlaender A; Pizzutillo P; Garassino MC; Addeo A
Transl Lung Cancer Res; 2020 Aug; 9(4):1533-1542. PubMed ID: 32953525
[TBL] [Abstract][Full Text] [Related]
6. SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.
Bamias A; Merseburger AS; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Calabrò F; Kramer M; de Velasco G; Zakopoulou R; Tzannis K; Sternberg CN
ESMO Open; 2021 Jun; 6(3):100152. PubMed ID: 33984672
[TBL] [Abstract][Full Text] [Related]
7. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
[TBL] [Abstract][Full Text] [Related]
9. Study on the predictive value of pretreatment peripheral blood inflammatory markers regarding immunotherapy in patients with inoperable advanced or locally advanced oesophageal squamous cell carcinoma.
Fu M; Li Z; Ma J; Shen F; Zhang X
Scand J Gastroenterol; 2024 Jun; 59(6):722-729. PubMed ID: 38362884
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment.
Da L; Qu Z; Zhang C; Shen Y; Huang W; Zhang Y; Gu K
Front Oncol; 2023; 13():1144875. PubMed ID: 37035159
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors.
Cao J; Chen Q; Bai X; Liu L; Ma W; Lin C; Lu F; Zhou T; Zhan J; Huang Y; Yang Y; Luo F; Zhao H
Ann Med; 2023; 55(2):2280002. PubMed ID: 38065623
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of systemic immune-inflammation index in patients with bone metastases from hepatocellular carcinoma treated with radiotherapy.
Chen J; Huang W; Xu X; Fan S; Zhang Q; Li X; Zeng Z; He J
Front Oncol; 2023; 13():1076428. PubMed ID: 37251953
[TBL] [Abstract][Full Text] [Related]
13. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
14. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
15. Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1-Based Therapy.
Li H; An X; Huang R; Li L; Chu C; Yang W; Qin Z; Liu Z; Zhou F; Xue C; Shi Y
Front Mol Biosci; 2021; 8():621883. PubMed ID: 34458319
[No Abstract] [Full Text] [Related]
16. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
[TBL] [Abstract][Full Text] [Related]
17. The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab.
Liu J; Gao D; Li J; Hu G; Liu J; Liu D
Onco Targets Ther; 2022; 15():1161-1170. PubMed ID: 36238132
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy.
Banna GL; Di Quattro R; Malatino L; Fornarini G; Addeo A; Maruzzo M; Urzia V; Rundo F; Lipari H; De Giorgi U; Basso U
Clin Transl Oncol; 2020 Nov; 22(11):2130-2135. PubMed ID: 32232716
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of PD-L2 Expression in Association with Neutrophil-to-Lymphocyte Ratio in Urothelial Carcinoma of the Bladder.
Hendri AZ; Soerohardjo I; Heriyanto DS; Khalilullah SA; Dany YA; Danurdoro A
Asian Pac J Cancer Prev; 2023 Aug; 24(8):2673-2679. PubMed ID: 37642053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
